This is of particular relevance since these therapies, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, the non-steroid mineralocorticoid receptor antagonist (ns-MRA) finerenone, and the glucagon-like peptide 1 (GLP1) agonist semaglutide, have shown not only to slow CKD progression in early stages of CKD, but also to prevent CVD. This evidence concerns the gene GCG and chronic kidney disease.